Evaluation of Plasma Cell‐Free Circulating DNA Integrity in Patients with Prostate Cancer in Jamaica

Abstract

Cell free circulating DNA (cfcDNA) is a promising diagnostic tool for prostate cancer (PCa). The study aimed to measure the cfcDNA concentration and cfcDNA integrity in prostate cancer patients using quantitative polymerase chain reaction (qPCR) analysis on plasma samples. The study also assessed correlation between cfcDNA concentration and integrity with baseline PSA, Gleason score, total prostate volume, age and the number of presenting comorbidities. Eleven patients with PCa and 9 patients with Benign Prostatic Hyperplasia (BPH) were enrolled. Plasma samples were collected before prostate biopsy and quantified by qPCR amplification of ALU115 DNA sequence, and the quantitative ratio of ALU 247 to ALU 115 reflected the integrity of cfcDNA. There were no significant differences in median (IQR) plasma cfcDNA concentration or its integrity between the patients with PCa [47.9 (214.93) ng/mL, 0.61 (0.49)] and patients with BPH [41.5 (55.13) ng/mL, 0.67 (0.45); p = 0.382, p = 0.342]. There was no correlation between cfcDNA and cfcDNA integrity with baseline PSA, Gleason score, total prostate volume, age and the number of presenting comorbidities.ConclusionThe small sample size of the current study did not allow for the differentiation of PCa from BPH using cfcDNA concentration and integrity. There was also no correlation with cfcDNA concentration and integrity with the selected clinical and pathological variables.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.